Methods for treating pulmonary inflammatory diseases

JP2020512287A5Inactive Publication Date: 2024-11-01DEFENSIN THERAPEUTICS APS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2019531167
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2016-12-13
Filing Date
2017-12-13
Publication Date
2024-11-01
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for pulmonary inflammatory diseases, such as asthma and COPD, are inadequate in preventing or treating inflammation and airway hyperresponsiveness, and there is a need for therapies that can be self-administered via the respiratory tract or administered to patients who cannot inhale medication.

Method used

Administration of mammalian α-defensins and β-defensins, such as human β-defensin 2 (hBD2), which reduce airway hyperresponsiveness, increase lung compliance, and normalize cytokine production to prevent cytokine storms, thereby treating or preventing inflammatory diseases by oral or pulmonary routes.

Benefits of technology

hBD2 effectively reduces inflammatory cell counts, cytokine levels, and lung inflammation, normalizing the immune response and preventing cytokine storms, offering a promising alternative to current treatments for pulmonary inflammatory diseases.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to methods for the treatment or prevention of asthma, mild intermittent asthma, mild persistent asthma, moderate persistent asthma, severe persistent asthma, eosinophilic asthma, neutrophilic asthma, steroid-resistant asthma, persistent asthma, pneumonia, bronchiectasis, COPD, sarcoidosis and lung cancer by administering mammalian alpha-defensins and / or beta-defensins to reduce airway hyperresponsiveness, increase lung compliance, decrease lung inflammation, reduce the number of inflammatory cells in bronchoalveolar lavage fluid, and reduce cytokine production. [Selection diagram] None
Need to check novelty before this filing date? Find Prior Art

Description

[Technology Field]

[0001] The present invention relates to a method for treating or preventing inflammatory lung diseases, including asthma, mild intermittent asthma, mild persistent asthma, moderate persistent asthma, severe persistent asthma, eosinophilic asthma, neutrophilic asthma, steroid-resistant asthma, persistent asthma, pneumonia, bronchiectasis, COPD, and lung cancer, by normalizing cytokine production and preventing cytokine storms through the administration of mammalian α-defensins and / or β-defensins, thereby reducing airway hyperresponsiveness, increasing lung compliance, reducing lung inflammation, reducing perivascular or peribronchial inflammation, reducing the number of inflammatory cells in bronchoalveolar lavage fluid, and restoring the balance of the immune system. [Background technology]

[0002] Asthma is a heterogeneous inflammatory disorder of the airways characterized by chronic inflammation, airway hyperresponsiveness, and recurrent wheezing, cough, and shortness of breath. Asthma is a major public health problem affecting 300 million people worldwide, with a significant increase in prevalence over the past 30 years, particularly in Western countries (Cosmi et al., 2011). However, the pathogenesis remains unknown. Combination therapy with steroids and long-acting β-agonists is central to asthma treatment. While these therapies effectively suppress acute inflammatory symptoms and cytokine release, there is currently no known preventive or curative treatment for the disease.

[0003] Mild to moderate allergic asthma is generally characterized by acute or chronic airway inflammation consisting of activated Th2 lymphocyte and eosinophil infiltration associated with IgE production, mucinous cells, thickening and metaplasia, airway wall remodeling, and airway hyperresponsiveness (AHR). AHR is characterized by increased responsiveness to nonspecific constrictive stimulants such as metacholine and airway narrowing (Hansbro et al., 2011). Th2 cells contribute to various pathological features of the disease, particularly through the secretion of cytokines IL-3, IL-4, IL-5, IL-9, and IL-13.

[0004] Severe asthma, neutrophilic asthma, or steroid-resistant asthma has different pathological features from mild to moderate allergic asthma and is characterized by a mixed Th2 / Th1 phenotype in which Th17 cells may contribute. Tumor necrosis factor (TNF)-α, interferon (IFN)-γ, IL-17, and IL-27 are elevated, and neutrophil (but not eosinophil) influx or mixed granulocyte airway infiltration characteristic of this subtype of asthma may occur. Patients with this subtype of asthma are resistant to glucocorticoid treatment, and both bacterial and viral infections are associated with disease induction and progression (Hansbro et al., 2004). In addition, patients with asthma and those with atopic dermatitis are more prone to developing infections, such as pneumonia, compared to non-atopic individuals.

[0005] The concept of treating asthma by targeting a single cytokine, such as anti-IL-4; anti-IL-5; or anti-TNF-α, has achieved limited success. In fact, steroid therapy, the current central therapy, is thought to work by suppressing broad pro-inflammatory pathways (Hansbro et al, 2011).

[0006] Chronic obstructive pulmonary disease (COPD) COPD is a major public health problem, projected to become the fourth leading cause of death worldwide by 2020. While sustained inhalation of toxic particles and gases is a major risk factor, and smoking is a prime example of this type of risk, only 15% of smokers develop COPD (Fletcher and Peto, 1977). Although smokers have a dysfunctional immune system (Bouloukaki et al., 2011), the development and increasing severity of COPD gradually worsens the inflammatory cellular load (Hogg et al., 2004).

[0007] Microbiome The microbiome of infants is initially homogeneous across various body parts, then transforms into site-specific communities over the following days and weeks. The lung microbiome of healthy adults is dominated by Bacteroides, Firmicutes, and Proteobacteria, with the main microbiome consisting of Pseudomonas, Streptococcus, Prevotella, Fusobacterium, Veillonella, Haemophilus, Neisseria, and Porphyromonas (Charlson et al, 2011). Among asthma patients, an increased frequency of Proteobacteria (especially Haemophilus, Moraxella, and Neisseria) and Firmicutes (especially Lactobacillus species) and a decreased frequency of Bacteroidetes (especially Prevotella) were observed compared to controls (Hilty et al., 2010). Similarly, epidemiological data show that the gastrointestinal microbiome differs between asthmatic and non-asthmatic infants (Penders et al., 2007).

[0008] Defensing Defensins represent one of the most powerful innate host defenses, working to maintain a healthy microbiome and prevent the emergence of potential pathogens (Wehkamp et al, 2002 and Salzman et al, 2007). Defensins are peptides with antimicrobial and anti-inflammatory activity against Gram-positive bacteria, Gram-negative bacteria, fungi, and archaea. Defensins, particularly hBD2, have shown therapeutic potential in the treatment of inflammatory bowel disease (WO2010 / 007166; WO2013 / 007596).

[0009] In conclusion, novel treatment methods are needed for patients suffering from inflammatory lung diseases. There is a particular need for treatment drugs that can be administered through the airway for patients who can self-administer medication, such as by inhalation, and for alternative routes of administration for patients who cannot efficiently inhale medication. [Overview of the project]

[0010] The inventors have surprisingly demonstrated that mammalian defensins have the ability to reduce airway hyperresponsiveness (AHR) and increase airway compliance (Cdyn); reduce pneumonia; reduce neutrophil, eosinophil, and macrophage counts in bronchoalveolar lavage fluid (BALF); and reduce IFN-γ, TNF-α, IL-4, IL-5, IL-6, IL-8, IL-9, IL-10, and IL-13 in lung cells. The inventors have also demonstrated efficacy in reducing tissue inflammation parameters in asthma models, such as reducing perivascular inflammation and peribronchial inflammation.

[0011] The data demonstrate that administration of mammalian defensins results in the normalization or reduction of key features of asthma, COPD, and sarcoidosis, and is therefore useful in the treatment or prevention of inflammatory lung diseases, including asthma, mild intermittent asthma, mild persistent asthma, moderate persistent asthma, severe persistent asthma, eosinophilic asthma, neutrophilic asthma, steroid-resistant asthma, persistent asthma, pneumonia, bronchiectasis, chronic obstructive pulmonary disease (COPD), and sarcoidosis.

[0012] Surprisingly, oral and intranasal administration of defensins were demonstrated to be equally effective for at least some of the parameters tested in a mouse model of house dust mite allergy. This opens up the possibility of treating inflammatory lung disease by oral administration in subjects who have difficulty inhaling drugs. As demonstrated in the examples, in a steroid-insensitive mouse model of asthma in which mice were sensitized to ovalbumin (OVA) and infected with C. muridarm, and in a steroid-sensitive mouse model in which mice were immunized with house dust mites (HDM) + Freund's adjuvant and loaded with HDM, administration of human β-defensin 2 (hBD2) was able to reduce AHR, increase Cdyn, reduce lung tissue inflammation, reduce the number of inflammatory cells in BALF, and reduce inflammatory cytokine production. Without treatment with hBD2, animals develop asthma characterized by a dramatic increase in AHR, a decrease in Cdyn, inflammatory tissue changes in lung tissue, an increase in white blood cell count, particularly neutrophils, eosinophils, and macrophages, and elevated inflammatory cytokine concentrations.

[0013] Based on these findings, the inventors also consider the broader and more common use of defensins in the treatment of lung inflammation. Examples of conditions that can cause lung inflammation include lung cancer, sarcoidosis, and various types of medical treatments that affect host defense, including but not limited to antimicrobial treatments, chemotherapy, immunotherapy, immunosuppressive therapy, and radiotherapy.

[0014] The inventors have experimentally demonstrated that defensins restore the balance of the immune system by completely normalizing cytokine levels, thereby preventing cytokine storms, in contrast to current asthma treatments such as interleukin antibodies that knock out a given cytokine or systemic immunosuppression that leads to systemic suppression of the innate immune system. Therefore, defensins represent a promising alternative to current treatment methods.

[0015] Furthermore, the inventors demonstrated that defensins can exert their effects in the lungs not only when administered directly to the lungs, but, more importantly and surprisingly, when simply administered orally to the gastrointestinal tract.

[0016] Oral administration for the treatment of asthma attacks and for maintenance therapy will ease the lives of asthma sufferers worldwide.

[0017] Accordingly, one embodiment provides a method for treating and / or preventing an inflammatory disease of the respiratory system, including restoring the balance of the immune system, normalizing cytokine production, and preventing a cytokine storm, comprising oral or intrapulmonary administration of at least one defensin, preferably in which the subject suffers from asthma.

[0018] In other embodiments, a method is provided for treating and / or preventing a disease selected from the group consisting of mild intermittent asthma, mild persistent asthma, moderate persistent asthma, severe persistent asthma, eosinophilic asthma, neutrophilic asthma, steroid-resistant asthma, persistent asthma, bronchiectasis, bronchitis, COPD, sarcoidosis, pneumonia and emphysema, and pulmonary fibrosis, preferably steroid-resistant asthma, comprising the administration of at least one defensin.

[0019] A method for treating and / or preventing lung cancer in a subject, comprising administering at least one defensin to the subject, and a method for reducing pulmonary tissue inflammation, perivascular and bronchial vascular inflammation, the number of inflammatory cells in bronchoalveolar lavage fluid and / or inflammatory cytokine production in lung tissue homogenetes in a subject where such reduction is necessary, comprising administering at least one defensin to the subject.

[0020] In yet another aspect, provided is a method for reducing lung tissue inflammation, reducing the number of inflammatory cells in bronchoalveolar lavage fluid, restoring the balance of the immune system by normalizing the production of inflammatory cytokines in lung tissue homogenates, and preventing / treating cytokine storm in a subject in need thereof, which method comprises administering at least one type of defensin to the subject.

[0021] In another aspect, provided is a method for increasing lung compliance, reducing airway hyperresponsiveness, and / or increasing peak flow in a subject in need thereof, which method comprises administering at least one type of defensin to the subject.

[0022] A method for increasing the forced expiratory volume in one second (FEV1) and / or the peak expiratory flow rate (PEFR) or reducing the PEFR variability in a subject in need thereof, which method comprises administering at least one type of defensin to the subject.

[0023] By administering at least one type of defensin to a subject in need thereof, the abundance of genes and the number of genera can be increased, the production of butyrate and / or tryptophan can be increased, and the production of acetate from the lung microbiota can be decreased.

[0024] Furthermore, provided is a method for maintaining and / or stabilizing the normal microbiota of the lung, increasing the prevalence and abundance of important symbiotic bacteria, and / or short-chain fatty acids and / or butyrate and / or tryptophan-producing strains in a subject in need thereof, which method comprises administering at least one type of defensin to the subject.

[0025] In other aspects, the present disclosure relates to the use of defensin polypeptides for use in a treatment method by any of the methods described herein and for the preparation of medicaments for the treatment of disorders as defined herein. BRIEF DESCRIPTION OF THE DRAWINGS

[0026]

Figure 1

Figure 2

Figure 3a

Figure 3b

Figure 4

Figure 5a - 5b

Figure 27

Figure 28

Figure 29

Figure 30

Figure 31

Figures 32 - 37

[0027] definition Defensins: As used herein, the term “defensin” refers to polypeptides belonging to the class defensins of antimicrobial peptides. Defensins represent one of the most powerful natural host defenses that work to maintain a healthy microbiome and prevent the emergence of potential pathogens (Wehkamp et al, 2002 and Salzman et al, 2007). Defensins are peptides that possess antimicrobial and anti-inflammatory activity against Gram-positive bacteria, Gram-negative bacteria, fungi, and archaea.

[0028] Human defensins are small cationic peptides classified into α-defensins and β-defensins based on the topology of their three intramolecular cysteine ​​disulfide bonds. α-defensins can be further classified into those expressed in neutrophil granules (HNP1-4) and those expressed by Paneth cells in the small intestinal crypts (HD5 and HD6 or DEFA5 and DEFA6). β-defensins (DEFBn) are primarily produced by epithelial cells in various tissues and organs, including the skin, eyes, middle ear, mouth, trachea, lungs, gastrointestinal tract, genitourinary system, kidneys, vagina, liver, pancreas, and mammary glands. Examples of defensins include human intestinal α-defensin 5 (HD5; SEQ ID NO: 5), human intestinal α-defensin 6 (HD6; SEQ ID NO: 6), human neutrophil peptide 1 (HNP-1), human neutrophil peptide 2 (HNP-2), human neutrophil peptide 3 (HNP-3), all belonging to the α-defensin class; as well as human β-defensin 1 (hBD1; SEQ ID NO: 1), human β-defensin 2 (hBD2; SEQ ID NO: 2), human β-defensin 3 (hBD3; SEQ ID NO: 3), human β-defensin 4 (hBD4; SEQ ID NO: 4), and cleaved human β-defensin 2 (SEQ ID NO: 7).

[0029] WO2013 / 026794 demonstrates that cleaved and uncleaved hBD2 have similar biological activity.

[0030] Defensins are expressed as precursors and processed by cleavage of signal peptides and, optionally, propeptides, before being secreted into the extracellular space. The most characterized members of the human β-defensin family are hBD1–4. Some human defensins (e.g., hBD1) are constitutively produced, while others (e.g., hBD2, hBD3, and hBD4) are induced by inflammatory cytokines or exogenous microbial products. The specific sequences mentioned above indicate the predicted mature, biologically active defensin. It will be understood by those skilled in the art that processing may differ between cells, and that the resulting secreted mature peptides may differ from the predicted sequence by one or two C or N-terminal amino acids but still retain biological activity.

[0031] Identity: The relationship between two amino acid sequences or two nucleotide sequences is described by the parameter "identity". The degree of identity between two amino acid sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J.Mol.Biol.48:443-453), as implemented in the EMBOSS package's needle program (Rice et al., 2000, http: / / emboss.org), preferably version 3.0.0 or later. The optional parameters used are a gap open penalty of 10, a gap extension penalty of 0.5, and the EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix. The needle-labeled "longest identity" output (obtained using the -nobreif option) is used as the percentage identity and calculated as (identical residues × 100) / (alignment length - total number of gaps in the alignment).

[0032] Normal microbiome: As used herein, the term “normal microbiome” refers to a microbiome that is not in a state of symbiotic imbalance. A normal microbiome is characterized by having a large genetic richness. A normal gut microbiome is characterized by containing bacteria belonging to the genera Bacteroides, Faecalibacterium, Rosebria, Brautia, Ruminococcus, Coprococcus, Bifidobacterium, Metanobrevibacter, Lactobacillus, Coprococcus, Clostridium, Akkermansia, and Eubacterium.

[0033] The normal lung microbiome is characterized by the presence of bacteria belonging to the genera Bacteroides, Firmicutes, and Proteobacteria, with the main microbiome consisting of Pseudomonas, Streptococcus, Prevotella, Fusobacterium, Veillonella, Haemophilus, Neisseria, and Porphyromonas.

[0034] Treatment: As used herein, the terms “treatment” and “to treat” refer to the management and care of a patient to counteract a symptom, disease, or disorder. The terms are intended to encompass the entire range of treatments for a given symptom suffered by a patient, including reducing or alleviating the symptom or complication; slowing the progression of the symptom, disease, or disorder; treating or eliminating the symptom, disease, or disorder; and / or administering an active compound to prevent the symptom, disease, or disorder, where “to prevent” or “prevent” should be understood to refer to the management and care of a patient to prevent or reduce the risk of developing the symptom or complication by interfering with or reducing the active compound. The patient to be treated is preferably a mammal, in particular a human. The patient to be treated may be of various ages.

[0035] Patient: A patient is a person who has been diagnosed with a specific disorder, such as inflammatory lung disorder, or who has specific symptoms indicating a disorder, such as inflammatory lung disorder.

[0036] Mammalian α-defensins and mammalian β-defensins This disclosure relates to the use of mammalian α-defensins and / or β-defensins, such as human β-defensins, more preferably hominin defensins, in the treatment of asthma, mild intermittent asthma, mild persistent asthma, moderate persistent asthma, severe persistent asthma, eosinophilic asthma, neutrophilic asthma, steroid-resistant asthma, persistent asthma, bronchiectasis, and COPD.

[0037] In one embodiment, the mammalian α-defensin and / or β-defensin has a degree of identity of at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% with any of the amino acid sequences of SEQ ID NOs: 1, 2, 3, 4, 5, 6, and 7. In another embodiment, the defensin differs from one of SEQ ID NOs: 1 to 7 by fewer than 10 amino acids, e.g., fewer than 8, e.g., fewer than 5, e.g., fewer than 4, e.g., fewer than 3, e.g., fewer than 2.

[0038] In a preferred embodiment, the human α-defensin comprises α-defensin 5 (SEQ ID NO: 5) and / or α-defensin 6 (SEQ ID NO: 6). In a preferred embodiment, the mammalian β-defensin comprises human β-defensin 1 (SEQ ID NO: 1), human β-defensin 2 (SEQ ID NO: 2), human β-defensin 3 (SEQ ID NO: 3), human β-defensin 4 (SEQ ID NO: 4), or cleaved human β-defensin 2 (SEQ ID NO: 7).

[0039] In a preferred embodiment, the human α-defensin has a degree of identity of at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% with the amino acid sequence of SEQ ID NO: 5. In a preferred embodiment, the human mammalian α-defensin consists of α-defensin 5 (SEQ ID NO: 5). In a preferred embodiment, the human β-defensin has a degree of identity of at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% with the amino acid sequence of SEQ ID NO: 2. In a preferred embodiment, the human β-defensin consists of human β-defensin 2 (SEQ ID NO: 2) or truncated human β-defensin 2 (SEQ ID NO: 7).

[0040] In yet another embodiment, the mammalian α-defensin comprises human α-defensin and / or mouse α-defensin, as well as functionally equivalent variants thereof. Preferably, the mammalian α-defensin comprises human α-defensin 5, human α-defensin 6, and functionally equivalent variants thereof. More preferably, the mammalian α-defensin comprises human α-defensin 5, and its functionally equivalent variants or orthologues.

[0041] In a further embodiment, the mammalian β-defensin comprises human β-defensin and / or mouse β-defensin, as well as functionally equivalent variants thereof. Preferably, the mammalian β-defensin comprises human β-defensin 1, human β-defensin 2, human β-defensin 3, human β-defensin 4, and their functionally equivalent variants. More preferably, the mammalian β-defensin comprises human β-defensin 2 and its functionally equivalent variants or orthologues.

[0042] In one embodiment, the method includes administering an effective dose of at least one mammalian α-defensin to a subject requiring such treatment.

[0043] A "functionally equivalent variant" of a mammalian (e.g., human) α-defensin or β-defensin is a modified mammalian (e.g., human) α-defensin or β-defensin that exhibits nearly the same effect on the microbiome in the lung or intestine as the original mammalian (e.g., human) α-defensin and / or β-defensin. Functionally equivalent variants of a mammalian (e.g., human) defensin may include 1 to 5 amino acid modifications, preferably 1 to 4 amino acid modifications, more preferably 1 to 3 amino acid modifications, most preferably 1 to 2 amino acid modifications, and especially 1 amino acid modification, compared to the mammalian (e.g., human) defensin amino acid sequence (e.g., any of SEQ ID NOs: 1 to 7). Preferably, for mammalian β-defensins, the comparison is made with human β-defensin 2 having SEQ ID NOs: 2 or truncated human β-defensin 2 (SEQ ID NOs: 7), and for α-defensins, the comparison is made with HD5 (SEQ ID NOs: 5).

[0044] In this specification, the term “modification” means any chemical modification of a mammalian (e.g., human) defensin. One or more modifications may be the substitution, deletion and / or insertion of one or more amino acids, as well as the exchange of one or more amino acid side chains; or the use of non-natural amino acids having similar properties in the amino acid sequence. In particular, one or more modifications may be amidations, such as C-terminal amidation. Preferably, amino acid modifications are minor, i.e., substitution or insertion of a conservative amino acid that does not significantly affect polypeptide folding and / or activity; a single deletion; a small amino-terminus or carboxyl-terminus extension; or a slight extension that facilitates purification by altering the net charge or by another function, such as a polyhistidine tag, antigenic epitope or binding domain. In one embodiment, a slight extension, such as a polyhistidine tag, antigen epitope, or binding domain, is attached to a mammalian (e.g., human) α-defensin or β-defensin by a small linker peptide of up to about 20–25 residues, the linker of which may include restriction enzyme cleavage sites.

[0045] Using the Clustal W alignment in Figure 3, we can predict which amino acid residues can be substituted without substantially affecting the biological activity of the protein. Sequences were aligned using Clustal W2.1 (http: / / www.geno.me.jp / tools / clustalw / ) with the following settings: Gap Open Penalty: 10, Gap Extension Penalty: 0,05, Weight Transition: NO, Hydrophilic residues of the protein: GPSNDQE, Hydrophilic gap: Yes, Weight matrix: BLOSUM (for PROTEIN). Substitutions within the following groups (Clustal W, "strong" conserved group) are considered conserved substitutions: S,T,A;N,E,Q,K;N,H,Q,K;N,D,E,Q;Q,H,R,K;M,I,L,V;M,I,L,F;H,Y;F,Y,W. The following group (Clustal W, "weak" conservation group) is considered a semi-conservative permutation: C,S,A;A,T,V;S,A,G;S,T,N,K;S,T,P,A;S,G,N,D;S,N,D,E,Q,K;N,D,E,Q,H,K;N,E,Q,H,R,K;V,L,I,M;H,F,Y.

[0046] Examples of conservative substitutions include those made within the groups of basic amino acids (arginine, lysine, and histidine), acidic amino acids (glutamic acid and aspartic acid), polar amino acids (glutamine and asparagine), hydrophobic amino acids (leucine, isoleucine, and valine), aromatic amino acids (phenylalanine, tryptophan, and tyrosine), and small amino acids (glycine, alanine, serine, threonine, and methionine). Amino acid substitutions that do not generally alter specific activity are well known in the art and have been described, for example, by Neurath and Hill (1979). The most commonly occurring exchanges are Ala / Ser, Val / Ile, Asp / Glu, Thr / Ser, Ala / Gly, Ala / Thr, Ser / Asn, Ala / Val, Ser / Gly, Tyr / Phe, Ala / Pro, Lys / Arg, Asp / Asn, Leu / Ile, Leu / Val, Ala / Glu, and Asp / Gly.

[0047] In addition to the 20 standard amino acids, non-standard amino acids (e.g., 4-hydroxyproline, 6-N-methyllysine, 2-aminoisobutyric acid, isovaline, and α-methylserine) may be substituted for amino acid residues in the wild-type polypeptide. A limited number of non-conservative amino acids, non-coding amino acids, and unnatural amino acids may also be substituted for amino acid residues. "Unnatural amino acids" are modified after protein synthesis and / or have different chemical structures in their side chains than those of standard amino acids. Unnatural amino acids can be chemically synthesized and are preferably commercially available, and include pipecolic acid, thiazolidinediocarcinol, dehydroproline, 3-methylproline and 4-methylproline, and 3,3-dimethylproline.

[0048] The essential amino acids in mammalian α-defensins and / or β-defensins can be identified by methods known in the art, such as site-directed mutagenesis or alanine scanning mutagenesis (Cunningham and Wells, 1989, Science 244:1081-1085). In the latter technique, a single alanine mutation is introduced at all residues in the molecule, and the resulting mutant molecule is tested for biological activity (i.e., activity against airway hyperresponsiveness or suppression of cytokines, e.g., TNF-α activity) to identify the amino acid residues important for the molecule's activity. See also Hilton et al., 1996, J. Biol. Chem. 271:4699-4708. The identity of essential amino acids can also be inferred from the analysis of the identity of mammalian α-defensins and / or β-defensins with associated polypeptides (see Clustal W alignment in Figure 3).

[0049] Single or multiple amino acid substitutions can be performed and tested using known methods of mutagenesis, recombination and / or shuffling, such as those disclosed by Reidhaar-Olson and Sauer, 1988, Science 241:53-57, Bowie and Sauer, 1989, Proc. Natl. Acad. Sci. USA 86:2152-2156, WO95 / 17413, or WO95 / 22625, followed by related screening methods. Other methods that may be used include error-prone PCR, phage display (e.g., Lowman et al., 1991, Biochem. 30:10832-10837; US 5,223,409; WO 92 / 06204), and region-directed mutagenesis (Derbyshire et al., 1986, Gene 46:145; Ner et al., 1988, DNA 7:127). If the results of a given substitution cannot be confidently predicted, the derivative may be easily analyzed according to the methods described herein to determine whether or not it is biologically active.

[0050] Long-acting defensins The half-life of an α-defensin or β-defensin may be extended by fusing or complexing the α-defensin or β-defensin with another moiety or molecule, i.e., by constructing a long-acting, biologically active α-defensin or β-defensin linked to a pharmacologically acceptable molecule, which provides a significantly increased in vivo plasma half-life of the α-defensin or β-defensin compared to the in vivo plasma half-life of an uncomplexed α-defensin or β-defensin administered similarly to the complexed α-defensin or β-defensin.

[0051] Long-acting bioactive α-defensins or β-defensins include mammalian α-defensins or their analogues or mammalian β-defensins or their analogues linked to pharmacologically acceptable molecules selected from neonatal Fc receptor (FcRn), transferrin, albumin (HAS), XTEN®; or PEG, homoamino acid polymer (HAP), proline-alanine-serine polymer (PAS), or negatively charged, highly acylated peptides such as elastin-like peptide (ELP), hyaluronic acid, carboxy-terminal peptide (CTP) of the chorionic gonadotropin (CG) β-chain, human IgG, and molecules having a linkage to CH3(CH2)nCO- (where n is 8 to 22).

[0052] The α-defensin analog or β-defensin analog may be of non-mammalian origin and may be selected from organic small molecules, peptides, polypeptides, and proteins.

[0053] Alpha-defensin or beta-defensin agonists may be linked to pharmacologically acceptable molecules by various methods described in the prior art literature, including, but not limited to, chemical linking by a bifunctional linker, or by genetic technology by linking the N-terminus or C-terminus of a defensin such as an alpha-defensin or beta-defensin to a pharmacologically acceptable molecule such as albumin or an albumin analog. In particular, the N-terminus of an albumin or albumin analog such as human albumin may be linked to the C-terminus of an alpha-defensin or beta-defensin, or to the N-terminus of an alpha-defensin or beta-defensin; or the C-terminus of an albumin such as human albumin may be linked to the C-terminus of an alpha-defensin or beta-defensin, or to the N-terminus of an alpha-defensin or beta-defensin. A linker sequence can be inserted between the albumin and the alpha-defensin chain or beta-defensin chain.

[0054] Alpha- or beta-defensin agonists may be linked to pharmaceutically acceptable molecules via stable or less stable linkers. Several linkers are known in the art and include bifunctional PEG molecules (see, e.g., Paige et al., Pharmaceutical Research, vol. 12, no. 12, 1995), hydrolyzable linkers (Shechter et al., Bioconjugate Chem. 2005, 16:913-920, and International Journal of Peptide Research and Therapeutics, Vol. 13, Nos. 1-2, June 2007, as well as W02009095479), PDPH, and EMCH (see, e.g., W02010092135). In certain cases where the chemical complexation (linking of two or more molecules) of an α-defensin or β-defensin agonist to a pharmacologically acceptable molecule strongly reduces the functional α-defensin or β-defensin activity, it may be preferable to use a more unstable linker that can release the functional α- or β-defensin agonist.

[0055] Half-life extension may also be achieved by acylation of the peptide backbone with spacers such as γ-L-glutamyl spacers and C-18 fatty acid chains to lysine. The fatty acid side chains and spacers mediate strong but reversible binding to albumin, delaying release from the injection site and reducing renal clearance.

[0056] Method and Use Human β-defensin 2 has been found to reduce airway hyperresponsiveness; increase lung compliance; decrease pneumonia; reduce neutrophil, eosinophil, and macrophage counts in the BALF; and restore balance to the immune system and prevent cytokine storms by normalizing IFN-γ, TNF-α, IL-4, IL-5, IL-6, IL-8, IL-9, IL-10, and IL-13 concentrations. As a result, it exhibits potent activity as a drug for the prevention or treatment of inflammatory lung diseases, such as asthma and COPD.

[0057] Surprisingly, parenteral and oral administration of defensins has been found to be effective in treating inflammatory lung diseases. This is unexpected because hBD2 is known not to be absorbed from the intestines, as demonstrated in Example 3 of this disclosure. The advantage of this finding is that patients with reduced lung capacity can take defensin medications orally. It is also anticipated that critically ill patients, such as those on ventilators and those with persistent asthma, can be treated with parenteral administration of at least one type of defensin.

[0058] Accordingly, in one embodiment, the present disclosure relates to a method for treating inflammatory lung disease by parenteral or oral administration of at least one type of defensin. Preferably, the administration is orally. Oral and parenteral administration are beneficial for patients with impaired respiration or those receiving mechanical ventilation.

[0059] In another embodiment, a method is provided for treating mild intermittent asthma, mild persistent asthma, moderate persistent asthma, severe persistent asthma, eosinophilic asthma, neutrophilic asthma, steroid-resistant asthma, persistent asthma, pneumonia, bronchiectasis, COPD, sarcoidosis, pulmonary fibrosis, or lung cancer by administering an effective dose of mammalian defensin to a subject requiring such treatment. These conditions can be treated by intrapulmonary, oral, or parenteral administration. Preferably, administration is intrapulmonary or oral.

[0060] The provided method can treat or prevent pneumonia by reducing leukocyte migration, such as neutrophils, eosinophils, and macrophages in BALF. Administration of hBD2 has been proven effective in reducing neutrophils and macrophages in BALF in particular.

[0061] This method restores the balance of the immune system by normalizing the production of cytokines such as IFN-γ, TNF-α, IL-4, IL-5, IL-6, IL-8, IL-9, IL-10, and IL-13 in, for example, lung tissue homogenates, and thus can prevent or treat cytokine storms in subjects suffering from one of the aforementioned diseases, as described herein. Preferably, this treatment method results in a reduction of cytokine production, where the cytokines are IFN-γ, TNF-α, IL-4, IL-5, IL-6, IL-9, IL-10, or IL-13. In particular, this method can reduce the amounts of IFN-γ, TNF-α, IL-4, IL-5, IL-9, and IL-13. The amount of cytokines can be determined in lung biopsy or BALF.

[0062] Furthermore, as described herein, this method can reduce airway hyperresponsiveness and increase lung compliance in subjects suffering from one of the aforementioned diseases.

[0063] The provided method can prevent or treat inflammation of the lungs of subjects suffering from one of the diseases described herein by altering the bacterial phenotype and the structure and composition of the lung microbiota or the lung metabolome through changes in transcription levels.

[0064] While not bound by theory, the effects observed using oral administration may be due to changes in the gastrointestinal microbiome and metabolome that can affect the lungs via the so-called gut-lung axis.

[0065] Chronic lung disorders such as asthma, COPD, and cystic fibrosis all exhibit components of intestinal disease symptoms, indicating significant crosstalk between these two mucosal sites in the human body, and suggesting that various respiratory diseases are related not only to the airway microbiota but also to imbalances in the gut microbiota (Marsland et al, 2015). Cesarean section birth is associated with a reduced diversity and alteration of the composition of the gut microbiota in early childhood, as well as an asthmatic predisposition during childhood (Jakobsson et al, 2014). Early exposure to environmental microorganisms prevents asthma (Ege et al, 2011), while early childhood and prenatal antibiotic exposure has been found to increase the risk of allergic asthma (Marra et al, 2009). The inverse correlation between childhood infections and the development of asthma and allergies has been recognized for many years, giving rise to the "hygiene hypothesis" that reduced exposure to infections in early childhood leads to abnormal immune tolerance and an increase in autoimmune symptoms (Wills-Karp et al, 2001).

[0066] A supplementary hypothesis is that changes in the composition of the gastrointestinal microbiota, resulting from antibiotic use and unhealthy diets (low fiber, high sugar) in Westernized regions, interfere with the gastrointestinal microbiome-mediated mechanisms of mucosal immune tolerance.

[0067] Symbiotic microorganisms modulate innate and adaptive immune responses and influence activation thresholds to pathogenic stimuli, primarily by producing small molecules that mediate host-microbe interactions (Donia and Fishback, 2015). While the epithelial barrier ensures that microorganisms are mainly confined to the gastrointestinal tract, microbial metabolites can cross the barrier, allowing them to enter and accumulate in the host circulatory system where they are detected by immune cells (Dorrestein et al, 2014). Trompette et al. (2013) demonstrated in mice that fermentable fiber in feed alters the composition of not only the gastrointestinal microbiota but also the lung microbiota, particularly the Firmicutes to Bacteroides ratio, which leads to increased local and systemic short-chain fatty acid levels, then affecting dendritic cell generation and function, thereby shaping the immune environment in the lung and influencing the severity of allergic inflammation. Schirmer et al. further demonstrated in the Human Genome Functional Analysis Project that inter-individual variability in cytokine responses is associated with specific microorganisms and microbial functions. The majority of the detected associations were both cytokine-specific and stimulus-specific, suggesting that the immune system recognizes and interacts with microorganisms and their products with high specificity, and that these microbial factors are associated with specific immunophenotypes. While TNF-α and IFN-γ production capacity appeared to be more strongly influenced by the microbiome, other cytokines such as IL-1β, IL-6, and Th17-derived IL-17 and IL-22 showed less but more specific associations with the gastrointestinal microbiome.

[0068] Further embodiments provide a method for preventing or treating mild intermittent asthma, mild persistent asthma, moderate persistent asthma, severe persistent asthma, eosinophilic asthma, neutrophilic asthma, steroid-resistant asthma, persistent asthma, pneumonia, bronchiectasis, COPD, or lung cancer by orally administering an effective amount of alpha-defensin and / or beta-defensin to subjects requiring such treatment. In preferred embodiments, asthma is steroid-resistant asthma. In one embodiment, administration is oral, intraoral, sublingual, rectal, vaginal, intratracheal, intrapulmonary, intranasal, intracranial, subcutaneous, intravenous, cutaneous, or transdermal. Preferably, administration is oral or intrapulmonary. Oral administration may be beneficial in patients with impaired respiration or those receiving mechanical ventilation.

[0069] Methods for treating asthma, mild intermittent asthma, mild persistent asthma, moderate persistent asthma, severe persistent asthma, eosinophilic asthma, neutrophilic asthma, steroid-resistant asthma, persistent asthma, bronchiectasis, and COPD are further provided, by administering effective doses of α-defensin and / or β-defensin parenterally, for example subcutaneously or intravenously, to subjects requiring such treatment.

[0070] The treatment methods described herein may be administered by administering a composition comprising at least one mammalian α-defensin and / or β-defensin in combination with any of the following: glucocorticoids, β-agonists, leukotriene receptor antagonists, theophylline, antibiotics, rifaximin, chemotherapy or immunotherapy, immunosuppressants, prebiotics, probiotics, tryptophan, short-chain fatty acids, HNP-1, HNP-2, HNP-3, HNP-4, cathelicidine, lactoferrin, lactoferricin, lysozyme, fecal transplantation, or any combination thereof. The defensins described herein can be used to alleviate one or more symptoms of antibiotics, chemotherapy, radiotherapy, immunotherapy, or immunosuppressive therapy. The defensins may be administered individually or in combination with one or more of these treatments. The defensins may be administered in combination with other drugs that can be used to treat asthma.

[0071] Importantly, the methods of the present disclosure can be used to treat, prevent or normalize a symbiotic imbalance of the microbiome / metabolome in the lungs of subjects who have received and / or are receiving antibiotic treatment or chemotherapy or immunotherapy or immunosuppressive therapy or radiotherapy or another treatment having a negative effect on the pulmonary microbiome or gut microbiome.

[0072] Normalizing the lung microbiome may involve activating the lung bacterial populations belonging to the genera Bacteroides, Firmicutes, and Proteobacteria, along with the main microbiome consisting of Pseudomonas, Streptococcus, Prevotella, Fusobacterium, Veillonella, Haemophilus, Neisseria, and Porphyromonas.

[0073] Normalizing the lung microbiome may involve altering the metabolome to one that produces relatively more tryptophan and / or butyrate and relatively less acetate.

[0074] Those eligible for treatment may experience asthma symptoms, including daily symptoms and persistent symptoms, less than twice per week.

[0075] Those being treated may be presenting with asthma attacks of varying severity, such as attacks affecting activity or attacks limiting physical activity, and / or with >2 episodes per week lasting several days, or >2 nocturnal asthma symptoms per month, such as frequent nocturnal symptoms.

[0076] In one embodiment, the subject to be treated has a one-second forced expiratory vital capacity (FEV1) of <80% of the predicted value, for example, an FEV1 of 60-80% or <60%.

[0077] Furthermore, the target may include maximum expiratory flow rate (PEFR) with fluctuations of >20%, for example, PEFR fluctuations of 20-30%, >30%, >60%, etc.

[0078] Subjects requiring treatment provided by the method of this disclosure may exhibit one or more of the following symptoms prior to treatment: Mild intermittent type: <2 symptoms per week Asymptomatic and normal peak flow rates (PEFR) during the interictal period. Short-duration seizures of varying intensity <2 nighttime symptoms per month >80% of predicted forced expiratory flow rate (FEV1) or PEFR <20% PEFR fluctuation Mild, persistent type: Symptoms occurring more than twice a week, but less than once a day. Exacerbations that may affect activity Nocturnal symptoms >2 times per month FEV1 >80% of predicted value PEFR fluctuation between 20% and 30% Moderately persistent: daily symptoms Daily use of short-acting β-agonists Seizures that affect activity Exacerbations may occur more than twice a week and may last for several days. Nocturnal symptoms >1 per week FEV1 is above 60% of the predicted value but below 80%. >30% PEFR fluctuation Severely persistent: Persistent symptoms Restricted physical activity Frequent exacerbations Frequent nighttime symptoms FEV1 <60% of predicted value >60% PEFR fluctuation

[0079] In one embodiment, the treatment results in improvement of at least one symptom such that the treated subject changes from severe persistent to moderate persistent, mild persistent, or mild intermittent. The treatment may also result in improvement of symptoms such that the treated subject changes from moderate persistent to mild persistent or mild intermittent, or from mild persistent to mild intermittent.

[0080] In other embodiments, defensins are used to treat lung inflammation associated with lung cancer. Lung cancer may be small cell lung cancer or non-small cell lung cancer (NSCLC). NSCLC may be selected from adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and bronchioloalveolar carcinoma. Administration of one or more defensins to lung cancer patients is expected to improve one or more inflammatory symptoms of the disease or one or more side effects of cancer treatment. Side effects of cancer treatment may be side effects of radiation, chemotherapy, immunotherapy, or surgery. It is also expected that administration of at least one α-defensin and / or β-defensin may reduce tumor cell proliferation by improving host defense in the lungs.

[0081] In vitro synthesis Mammalian α-defensins and mammalian β-defensins can be produced by ex vivo synthesis using conventional methods known in the art. Various commercially available synthesizers are available, including automated synthesizers from companies such as Applied Biosystems Inc. and Beckman Inc. By using synthesizers, native amino acids can be substituted with non-native amino acids, particularly D-isomers (or D-types) of D-alanine and D-isoleucine, diastereoisomers, and side chains of different lengths or functionalities. The specific sequence and preparation method are determined by convenience, cost-effectiveness, and required purity. Chemical linkages may be conferred to various peptides or proteins containing functionalities convenient for linkage, such as amino groups for amide or substituted amine formation, e.g., amino groups for reductive amination, thiol groups for thioether or disulfide formation, and carboxyl groups for amide formation. If necessary, various groups may be introduced into the peptide during synthesis or expression, enabling linkage to other molecules or to surfaces. Therefore, cysteine ​​can be used to obtain thioethers, histidine for bonding to metal ion complexes, carboxyl groups for forming amides or esters, and amino groups for forming amides, and so on.

[0082] Mammalian α-defensins and mammalian β-defensins, or their functional equivalents, may also be isolated and purified according to conventional methods of recombinant synthesis. Recombinant synthesis may be carried out using appropriate expression vectors and eukaryotic expression systems. Solutions may be prepared from the expression host and culture medium, and the defensins present may be purified using HPLC, exclusion chromatography, gel electrophoresis, affinity chromatography, or other purification techniques. A method for recombinant expression of human β-defensin 2 in Escherichia coli is disclosed in WO2010 / 007166 (Novozymes).

[0083] Mammalian α-defensins and β-defensins may also be induced by administration of their corresponding mRNAs.

[0084] Dosage Mammalian α-defensins, such as human α-defensins and human β-defensins, are preferably used in amounts effective for treating general lung inflammation or in amounts effective for treating mild intermittent asthma, mild persistent asthma, moderate persistent asthma, severe persistent asthma, eosinophilic asthma, neutrophilic asthma, steroid-resistant asthma, persistent asthma, bronchiectasis, COPD, or lung cancer, preferably with tolerable toxicity to the patient. Mammalian α-defensins, such as human α-defensins and human β-defensins, are also preferably used in amounts effective for maintaining the composition of a normal microbiome in the lungs and / or intestines, or for treating or normalizing a symbiotic imbalance in the microbiome of the lungs and / or intestines, preferably with tolerable toxicity to the patient requiring treatment.

[0085] Such treatments require appropriate dosages, which vary depending on factors such as the chemical properties and pharmacokinetic data of the compounds used, the individual host, the mode of administration, and the nature and severity of the symptoms being treated.

[0086] However, generally speaking, the desirable daily dose of human α-defensin for satisfactory results in mammals, such as humans, is preferably about 0.1 mg HD5 / kg body weight to about 10 mg HD5 / kg body weight, more preferably about 0.5 mg HD5 / kg body weight to about 10 mg HD5 / kg body weight, more preferably about 1.2 mg HD5 / kg body weight to about 10 mg HD5 / kg body weight, preferably about 1.2 mg HD5 / kg body weight to about 5 mg HD5 / kg body weight, and even more preferably 1.2 mg HD5 / kg body weight, administered, for example, in divided doses up to 1, 2, or 3 times a day.

[0087] In one embodiment, the desired daily dose of human β-defensin is preferably about 0.1 mg hBD2 / kg body weight to about 10 mg hBD2 / kg body weight, more preferably about 0.5 mg hBD2 / kg body weight to about 10 mg hBD2 / kg body weight, more preferably about 1.2 mg hBD2 / kg body weight to about 10 mg hBD2 / kg body weight, preferably about 1.2 mg hBD2 / kg body weight to about 5 mg hBD2 / kg body weight, and even more preferably 1.2 mg hBD2 / kg body weight, and is administered, for example, in divided doses up to 1, 2, or 3 times a day.

[0088] When two different defensins are administered in a single dose, the dose may contain equal or nearly equal amounts of the two defensins, determined by weight or molar basis. The ratio may also vary, for example, from 2:1 to 1:2, such as 10:1 to 1:10, 5:1 to 1:5, etc., determined by weight or molar basis, where the ratio of α-defensin to β-defensin is 10:1 to 1:10, 5:1 to 1:5, etc.

[0089] The compounds of the preferred embodiment can be administered to large mammals, such as humans, in the same dosage and manner as those conventionally used.

[0090] In one embodiment, a method is provided in which the daily dose is 0.1 to 10 mg defensin / kg, for example 0.5 to 5 mg defensin / kg, for example 1 to 2 mg defensin / kg, for example 1.2 mg defensin / kg per day, as described herein.

[0091] In certain embodiments, the pharmaceutical composition of the preferred embodiment may contain mammalian α-defensins and / or mammalian β-defensins, such as human α-defensin and / or human β-defensin, in amounts of about 0.5 mg or less to about 1500 mg or more per unit dosage form, preferably about 0.5, 0.6, 0.7, 0.8 or 0.9 mg to about 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900 or 1,000 mg, more preferably about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 or 25 mg to about 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 mg. In certain embodiments, however, lower or higher doses than those described above may be preferred. Preferred concentrations and doses can be readily determined by those skilled in the art. In certain embodiments, the preferred embodiment of the pharmaceutical composition comprises a mammalian α-defensin, such as human α-defensin. In certain embodiments, the preferred embodiment of the pharmaceutical composition comprises a mammalian β-defensin, such as human β-defensin. In further embodiments, the preferred embodiment of the pharmaceutical composition comprises a mammalian α-defensin and a mammalian β-defensin, such as human α-defensin and human β-defensin, where the α-defensin and β-defensin are present in equal amounts on a molar basis or on a mg / mL basis.

[0092] In one embodiment, mammalian α-defensins and / or β-defensins are administered at least once a day, at least twice a day, for example, at least three times a day, or continuously.

[0093] In one embodiment, mammalian α-defensins and / or β-defensins are administered intravenously by continuous infusion or intrapulmonaryly by continuous mechanical ventilation in patients on external ventilators.

[0094] Formulation for oral or parenteral administration Mammalian α-defensins or β-defensins can be therapeutically used in compositions formulated for administration via any common route. In one embodiment, administration of at least one mammalian β-defensin is generally intranasal according to the method of this disclosure. Intranasal administration is standard as pulmonary drug delivery.

[0095] In one embodiment, administration of at least one mammalian α-defensin and / or at least one mammalian β-defensin is by oral administration according to the method of the present disclosure.

[0096] In one embodiment, administration of at least one mammalian α-defensin and / or at least one mammalian β-defensin is subcutaneous or intravenous according to the method of the present disclosure.

[0097] In some embodiments, the compositions of the preferred embodiments may be formulated as lyophilized products and as lyophilized products with appropriate excipients to provide stability after rehydration. Pharmaceutical compositions containing mammalian α-defensins and / or mammalian β-defensins, such as human α-defensins and / or human β-defensins, can be produced by conventional methods, for example, by mixing, granulation, coating, dissolution, or lyophilization steps. In preferred embodiments, pharmaceutical compositions containing mammalian α-defensins and / or mammalian β-defensins are formulated as sterile isotonic solutions.

[0098] Pharmaceutically acceptable carriers and / or diluents are known to those skilled in the art. With respect to compositions formulated as liquid solutions, acceptable carriers and / or diluents should include physiological saline and sterile water, and the composition may optionally contain antioxidants, buffers, bacteriostatic agents, and other common additives.

[0099] The compounds of this disclosure can be formulated into a wide variety of formulations for oral administration. Solid preparations may include powders, tablets, drops, capsules, cachets, licks, and dispersible granules. Other dosage forms suitable for oral administration may include liquid preparations, such as emulsions, syrups, elixirs, aqueous solutions, aqueous suspensions, toothpastes, toothpaste gels, and chewing gums, or solid preparations that are intended to be converted immediately before use into liquid preparations such as solutions, suspensions, and emulsions.

[0100] The compounds of this disclosure can be formulated in a wide variety of dosage forms for intranasal, subcutaneous, or intravenous administration. The formulations may contain carriers, bulking agents, disintegrants, flow modifiers, sugars and sweeteners, flavorings, preservatives, stabilizers, wetting agents, emulsifiers, solvents, salts for adjusting osmotic pressure, buffers, diluents, dispersants and surfactants, binders, lubricants, and / or other pharmaceutical excipients known in the art. Those skilled in the art can further formulate mammalian α-defensins and mammalian β-defensins in appropriate ways and in accordance with accepted practices such as those described in Remington's Pharmaceutical Sciences, Gennaro (1990).

[0101] Mammalian alpha-defensins and mammalian beta-defensins, such as human alpha-defensins and human beta-defensins, can be used alone or in combination with one or more other pharmaceutical compounds or active pharmaceutical ingredients, for example, with glucocorticoids, beta-agonists, leukotriene receptor antagonists, theophylline, antibiotics, chemotherapy or immunotherapy or a combination thereof, and / or with one or more pharmacologically acceptable excipients.

[0102] Airway administration Airway administration may be used to administer the compositions of this disclosure. Intrapulmonary administration means local administration to the lungs. As used herein, the terms “intratracheal administration, intrabronchial administration or intraalveolar administration” include all forms of such administration in which defensin is applied to the trachea, bronchi, or alveoli, respectively, by drip infusion of a defensin solution, by application of defensin in powder form, or by inhalation of defensin to enable it to reach the appropriate portion of the airway.

[0103] Methods of intrabronchial / intraalveolar administration include, but are not limited to, bronchoalveolar lavage (BAL) by methods known to those skilled in the art using a lavage solution in which defensin is dissolved as a physiologically acceptable composition, or by any other effective form of intrabronchial administration, including the use of an inhalation powder containing defensin in dry form, with or without excipients, or direct application of defensin in solution, suspension or powder form during bronchoscopy. Methods of intratracheal administration include, but are not limited to, blind tracheal lavage with a solution or suspension of dissolved defensin, or inhalation of spray droplets containing dissolved defensin or suspension obtained by using any spray device suitable for this purpose.

[0104] In other embodiments, intratracheal, intrabronchial, or intraalveolar administration does not involve inhalation of the product but includes the drip infusion or application of a defensin solution or a defensin-containing powder or gel into the trachea or lower airway.

[0105] Other preferred methods of administration may include the use of the following devices: 1. Pressurized sprayer using compressed air / oxygen mixture 2.Ultrasonic atomizer 3. Electronic micropump sprayer 4. Metered dose inhaler (MDI) 5. Dry Powder Inhalation System (DPI)

[0106] Aerosols may be delivered during mechanical ventilation (devices 1, 2, and 3) either a) via a face mask or b) via an endotracheal tube in intubated patients. Devices 4 and 5 may also be used by the patient without assistance, provided that the patient is able to operate the spraying device themselves.

[0107] The preferred concentration of a solution containing defensin and / or a functional homolog or variant of defensin is in the range of approximately 0.1 μg to 1000 μg per ml of solution, or approximately 0.1 μg to 250 μg per ml of solution.

[0108] Pharmaceutical composition for intrapulmonary administration Pharmaceutical compositions or formulations for use in this disclosure include defensins, preferably dissolved in a pharmaceutically acceptable carrier, preferably an aqueous carrier or diluent, or defensins delivered to the lower respiratory tract as pegylated preparations, or as liposomes or nanoparticle preparations administered as an inhaled aerosol, or as a lavage solution administered via bronchoscopy as bronchoalveolar lavage or as a blind intratracheal wash or lavage. Various aqueous carriers may be used, including but not limited to 0.9% saline, buffered saline, and physiologically compatible buffers. The compositions may be sterilized by conventional techniques known to those skilled in the art. The resulting aqueous solutions may be packaged for use, or filtered and lyophilized under sterile conditions, and the lyophilized preparations may be dissolved in a sterile aqueous solution before administration.

[0109] In one embodiment, the lyophilized defensin preparation may be pre-packaged, for example, in single-dose units. In a more preferred embodiment, the single-dose units are adjusted for the patient.

[0110] The composition may contain pharmacologically acceptable adjuvants or auxiliary agents, including but not limited to pH adjusters and buffers and / or isotonic agents, such as sodium acetate, sodium lactate, sodium chloride, potassium chloride, and calcium chloride.

[0111] The formulation may contain pharmacologically acceptable carriers and excipients, including microspheres, liposomes, microcapsules, and nanoparticles. Conventional liposomes are typically composed of phospholipids (neutral or negatively charged) and / or cholesterol. Liposomes are vesicular structures based on a lipid bilayer surrounding an aqueous compartment. Liposomes can differ in their physiological and chemical properties, such as the size of the phospholipid bilayer, lipid composition, surface charge and number, and fluidity.The lipids most frequently used for liposome formation are: 1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimiristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), and 1,2-dimiristoyl 1,2-sn-glycero-3-phosphoethanolamine (DMPE), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dimyristoyl-sn-glycero-3-phosphate (monosodium salt) (DMPA), 1,2-dipalmitoyl-sn-glycero-3-phosphate (monosodium salt) (DPPA), 1,2-dioleoyl-sn-glycero Cello-3-phosphate (monosodium salt) (DOPA), 1,2-dimyristoyl-sn-glycero-3-[phospho-rac-(1-glycerin)](sodium salt) (DMPG), 1,2-dipalmitoyl-sn-glycero-3-[phospho-rac-(1-glycerin)](sodium salt) (DPPG), 1,2-dioleoyl-sn-glycero-3-[phospho-rac-(1-glycerin)](sodium salt) (DOPG), 1,2-dimyristoyl-sn-glycero -3-[phospho-L-serine](sodium salt)(DMPS), 1,2-dipalmitoyl-sn-glycero-3-[phospho-L-serine](sodium salt)(DPPS), 1,2-dioleoyl-sn-glycero-3-[phospho-L-serine](sodium salt)(DOPS), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(glutaryl)(sodium salt), and 1,1',2,2'-tetramyristoylcardiolipin(ammonium salt). Formulations comprising DPPC in combination with another lipid or liposome modifier are preferably, for example, in combination with cholesterol and / or phosphatidylcholine.

[0112] Long-circulating liposomes are characterized by their ability to extravasate in body parts where vascular wall permeability is increased. The most common method for generating long-circulating liposomes is to covalently bond the hydrophilic polymer polyethylene glycol (PEG) to the outer surface of the liposomes. Some preferred lipids include: 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000](ammonium salt), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-5000](ammonium salt), and 1,2-dioleoyl-3-trimethylammonium-propane(chloride salt)(DOTAP).

[0113] Lipids that may be applicable to liposomes are supplied by Avanti, Polar Lipids, Inc., Alabaster, AL. Furthermore, the liposome suspension may contain lipid protectants to protect the lipids from damage caused by free radicals and lipid peroxidation during storage. Lipid-soluble free radical inactivators such as α-tocopherol and water-soluble iron-specific chelating agents such as ferrioxamine are preferred.

[0114] For example, various methods can be used to prepare liposomes, as described in Szoka et al., Ann. Rev. Biophys. Bioeng. 9:467 (1980), U.S. Patent Nos. 4,235,871, 4,501,728 and 4,837,028, all of which are incorporated herein by reference. Another method generates heterogeneous multi-membrane vesicles. In this method, vesicle-forming lipids are dissolved in a suitable organic solvent or solvent system and dried under vacuum or inert gas to form a thin lipid membrane. If desired, this membrane may be dissolved again in a suitable solvent such as tertiary butanol and then freeze-dried to form a more homogeneous lipid mixture in a powder-like form that is more readily hydrated. This membrane is covered with an aqueous solution of the target drug and targeting component and can usually be hydrated over a period of 15 to 60 minutes with stirring. The size distribution of the resulting multilayer thin-film vesicles can be shifted to even smaller sizes by hydrating the lipids under more vigorous shaking conditions, or by adding solubilizing surfactants such as deoxycholate.

[0115] Micelles are formed in aqueous solutions by surfactants (molecules containing a hydrophobic moiety and one or more ionic or strongly hydrophilic groups).

[0116] Common surfactants known to those skilled in the art can be used in the micelles of the present invention. Preferred surfactants include sodium laurate, sodium oleate, sodium lauryl sulfate, octaoxyethylene glycol monododecyl ether, octoxynol 9, and PLURONIC F-127 (Wyandotte Chemicals Corp.). Preferred surfactants are nonionic polyoxyethylene surfactants and polyoxypropylene surfactants suitable for intravenous injection, such as TWEEN-80, PLURONIC F-68, and n-octyl-β-D-glucopyranoside. Furthermore, phospholipids, such as those described for use in the production of liposomes, may be used for micelle formation.

[0117] Examples Example 1 Determination and evaluation of the efficacy of mammalian β-defensins in a mouse model of steroid-insensitive neutrophilic allergic airway disease with severe infection-induced asthma (Figure 1)

[0118] material and method Treatment method: Female BALB / c mice aged 6-8 weeks were sensitized intraperitoneally (IP) to 50 μg of ovalbumin in 200 μL of 0.9% saline containing 1 mg of alum adjuvant. The mice were intranasally (IN) inoculated with ovalbumin (10 μg in 50 μL of sterile saline) on days 12-13 and 33-34. On day 14, the mice were inoculated IN with Chlamydia muridarum, a natural mouse pathogen (Cmu: 100 inclusion body forming units, ATCCVR-123, 30 μL of sucrose phosphate glutamate buffer (SPG)). Dexamethasone (DEX) was administered IN on days 32-34 along with the ovalbumin inoculation (2 mg / kg; 50 μL of phosphate-buffered saline (PBS)). hBD2 was administered intravenously on days 30, 32, and 34 (5 mg / kg; 50 μL phosphate-buffered saline).

[0119] Drugs administered to mice via intranasal delivery are expected to reach the lungs via the airways, and this is an approved model in the field of pulmonary administration.

[0120] test: Airway inflammation: Leukocyte percentages were obtained from Meiglünwald-Giemsa stained BALF cells using a light microscope.

[0121] Lung function: AHR was measured in anesthetized mice with cannula insertion using the Scireq Flexivent FX1 system. Data are presented as airway resistance at 10 mg / kg methacholine and as dose-response curves.

[0122] result Airway inflammation: Mice sensitized with ovalbumin and infected with C. muridarm showed highly statistically significant increases in total leukocytes, macrophages, lymphocytes, neutrophils, and smaller eosinophils. The group treated with hBD2 in IN showed complete normalization of neutrophil counts and smaller lymphocyte counts, while macrophages and eosinophils remained unchanged. The group treated with DEX in addition to hBD2 in IN showed complete normalization of eosinophils, but no other additive effects were observed (Figure 7).

[0123] Lung function: Mice sensitized with ovalbumin (Ova) had a higher AHR compared to the saline (Sal) (non-asthmatic) control group. This difference was statistically highly significant. The INhBD2-treated group (Cmu / Ova / hBD2) showed a completely normalized AHR comparable to the saline control group. The group treated with DEX in addition to hBD2 in IN showed a completely normalized AHR comparable to the saline control group, but DEX did not appear to have an additive effect (Figure 4).

[0124] Conclusion: This example demonstrates that intranasal administration of hBD2 can completely normalize airway hyperresponsiveness and neutrophil count in BALF in a known steroid-resistant animal model of asthma.

[0125] Example 2 Determination and evaluation of the efficacy of orally administered versus in-vitro administered mammalian β-defensins in a mouse house dust mite / Freund's complete adjuvant-induced model of allergic asthma (Figure 2)

[0126] material and method Treatment method: Female BALB / c mice aged 7-10 weeks were randomly assigned to one of seven test groups one day before the start of the study and subcutaneously (SC) sensitized to house dust mites (100 μg HDM in 200 μL of saline and Freund's complete adjuvant in 0.9% saline). Following the mice, HDM was administered intranasally (IN) on day 14 (25 μg HDM in 50 μL of saline). Dexamethasone was administered orally on day 14 (1 mg / kg BID; 50 μL phosphate-buffered saline (PBS)). hBD2 was administered intranasally or orally on day 14 (1.7 mg / kg TID IN; 0.4 mg / kg TID IN; 0.4 mg / kg TID oral, 50 μL phosphate-buffered saline). The initial dose was administered 60 minutes before the load, and subsequent doses were administered at approximately 6-hour intervals.

[0127] test: Airway inflammation: 48 hours after the load, bronchoalveolar lavage was performed, and the lungs were washed with three volumes of cold PBS (0.4; 0.3 and 0.3 mL (total 1 mL)). Total white blood cell count and white blood cell percentage were determined using an automated blood analyzer, Sysmex XT-2000iV.

[0128] Lung function: Starting 48 hours after HDM loading, lung resistance and lung compliance were measured using the Buxco Finepointe RC system from DSI in anesthetized mice with inserted cannulas after metacholine loading (MCH1, 3.125 mg / mL; MCH2, 6.25 mg / mL; MCH3, 12.5 mg / mL; and MCH4, 25 mg / mL). Data are presented as airway resistance at 10 mg / kg of metacholine and as dose-response curves.

[0129] Lung aspiration for cytokine analysis: After all BAL procedures were completed, the lungs were removed from the thoracic cavity, rapidly frozen in liquid nitrogen, and stored at -80°C until cytokine concentrations of IL-1β, TNF-α, IL-6, IL-10, and IFNγ were analyzed by ELISA.

[0130] result In animals treated with HDM-loaded media, increased lung resistance and decreased lung compliance were observed compared to saline-loaded (non-asthmatic) mice. Inflammatory responses in mice treated with both media (oral and intranasal) were triggered by a single HDM load 14 days after sensitization with HDM and the adjuvant. The inflammatory response was characterized by a statistically significant increase (p<0.05) in total cell count, eosinophil count, neutrophil count, macrophage count, and lymphocyte count in the lung tissue homogeneous compared to the saline-loaded control. Furthermore, concentration analysis of five cytokines—IL-1β, TNF-α, IL-6, IL-10, and IFN-γ—in lung tissue homogenees revealed significantly higher levels in HDM-loaded animals compared to the saline-loaded control.

[0131] Dexamethasone treatment significantly suppressed total cell count and eosinophil count in BALF, but not significantly suppressed neutrophil, macrophage, or lymphocyte counts. Consistent with cellular data, dexamethasone did not affect the levels of IL-1β, TNF-α, IL-6, IL-10, and IFN-γ in lung tissue homogeneous compared to HDM / vector controls. However, dexamethasone did affect AHR measurements related to eosinophil count. The results suggest that this model is somewhat steroid-resistant.

[0132] The test item hBD2 effectively suppressed increased airway resistance (Figures 5a and 5b) and decreased lung compliance (Figures 6a and 6b) compared to animals treated with HDM-loaded media, both after three oral and intranasal administrations on day 14. More pronounced effects were observed in several parameters after intranasal administration; for example, in cellular influx in the BALF, both doses (0.4 mg / kg / day TID and 1.7 mg / kg / day TID) significantly suppressed neutrophil count. Dexamethasone, the standard steroid, did not suppress neutrophil count. Similar significant effects were observed in IL-6, IL-10, and IFN-γ cytokine levels in lung tissue homogenates for both administration routes (Figures 9, 14, and 17). Orally administered hBD2 significantly reduced TNF-α (Figure 10), while intranasally administered hBD2 did not significantly differ from the control. Figure 11 shows the effect on IL-1β.

[0133] Conclusion: All results demonstrate the clear anti-inflammatory effect of hBD2 in a house dust mite / Freund's complete adjuvant-induced mouse model of allergic asthma. Surprisingly, orally administered hBD2 was also effective in treating asthma and reducing inflammation in asthmatic mice.

[0134] Example 3 Determination and evaluation of the efficacy of orally administered versus in-vitro administered mammalian β-defensins in a mouse house dust mite / Freund's complete adjuvant-induced model of allergic asthma (Figure 2)

[0135] material and method Treatment method: Female BALB / c mice aged 7–10 weeks were randomly assigned to four test groups one day before the start of the study and subcutaneously (SC) sensitized to house dust mites (100 μg of HDM in 200 μL of saline and Freund's complete adjuvant in 0.9% saline). On day 14, the mice were administered HDM intranasally (IN) (25 μg of HDM in 50 μL of saline). hBD2 was administered intranasally or orally on day 14 (0.4 mg / kg TID IN; 0.4 mg / kg TID orally, in 50 μL phosphate-buffered saline). The initial dose was administered 60 minutes before the dose, and subsequent doses were administered at approximately 6-hour intervals.

[0136] test: Lung tissue collection: The lungs were removed from the thoracic cavity, rapidly frozen in liquid nitrogen, and stored at -80 degrees Celsius until cytokine concentration analysis of IL-4, IL-5, IL-8(KC), IL-9, and IL-13 was performed by ELISA.

[0137] The lungs were inflated in situ in 10% buffered formalin, removed from the thoracic cavity, individually placed in 10% buffered formalin, then embedded together in paraffin, sectioned, and stained with H&E / PAS.

[0138] blood sampling All terminal blood samples were collected via transvenous blood collection. The blood was collected in lithium heparin tubes, placed on ice, and immediately centrifuged at 4°C. Plasma was separated and stored at -80°C until future SCFA analysis.

[0139] Lung tissue sample collection The lungs were exposed and removed by gently incising the chest and cutting off both sides of the sternum and ribs. Lungs from the first six animals in each group were removed from the rib cage, rapidly frozen in liquid nitrogen, and stored at -80°C until cytokine concentration analysis by ELISA.

[0140] Lungs from eight other animals per group were inflated in situ with 10% buffered formalin, removed from the thoracic cavity, individually placed in 10% buffered formalin, and then embedded together in paraffin. The sections were then sectioned and stained with H&E / PAS. The paraffin blocks were stored for IHC analysis.

[0141] reading Histopathology (H&E;PAS) (N=8 / group; total N=32) Cytokines (IL-4, IL-5, KC, IL-9, and IL-13) in lung tissue homogenates (N=6 / group; total N=24)

[0142] histopathology Cellular influx (mononuclear cells, eosinophils, neutrophils) was individually evaluated semi-quantitatively on H&E-stained slides in the peribronchial / bronchiolar and perivascular spaces as follows: 0 None 1. A small number of scattered inflammatory cells 2 Larger aggregates 3. Significant accumulation of cells The overall inflammation score was calculated as the sum of the scores for all individuals. Goblet cell metaplasia was evaluated separately at the major and peripheral airway levels using PAS-stained slides as follows: 0 No mucus-containing cells along the basement membrane 1. A small number of positive cells with less than 75% stained cytoplasm along the basement membrane. 2. A small number of positive cells with more than 75% stained cytoplasm along the basement membrane. 3. Numerous positive cells with less than 75% stained cytoplasm along the basement membrane. 4. Numerous positive cells with more than 75% stained cytoplasm along the basement membrane.

[0143] Statistical evaluation The data was processed using MS Excel. Statistical analysis was performed using GraphPad Prism software (version 5.04). Differences between groups were considered statistically significant if p < 0.05.

[0144] Statistical analysis of the selected histological score values ​​(data) was performed using the median and the nonparametric Mann-Whitney test.

[0145] result In mice treated with both media (oral and intranasal), inflammatory responses were induced by a single HDM load 14 days after sensitization with HDM and the adjuvant. The inflammatory response was characterized by statistically significant increases in the concentrations of five cytokines, IL-4, IL-5, IL-8, IL-9, and IL-13, in lung tissue homogenetes in HDM-loaded animals compared to saline-loaded controls, and by severe histological inflammatory changes in lung tissue.

[0146] The test product hBD2 effectively suppressed the increase in tissue inflammation in lung tissue compared to animals treated with HDM-loaded media, both after three oral and intranasal administrations on day 14 (Figures 19, 20, 21). Similar significant effects were observed on IL-4, IL-5, IL-8, IL-9, and IL-13 cytokine levels in lung tissue homogenates from both administration routes (Figures 12, 13, 15, 16, 18).

[0147] Conclusion: All results obtained demonstrate the clear anti-inflammatory effect of hBD2 in a house dust mite / Freund's complete adjuvant-induced mouse model of allergic asthma. This effect was obtained using both intranasal and oral administration of hBD2.

[0148] Example 4 Pharmacokinetic study to establish the pharmacokinetic profile of hBD2 after a single oral enteral nutrition administration of 4 mg / kg to NMRI mice.

[0149] material and method Procedure: Twenty-one female NMRI mice were administered 5 ml / kg of oral enteral nutrition using a gaseous tube and a 1 ml syringe, according to their individual body weight on the day of administration. Urine was collected at random time points by gently massaging the inguinal region of the abdomen. A first blood sample was obtained using the submandibular gland collection method. A second blood sample was collected from mice anesthetized with isoflurane. Intestinal samples were obtained after euthanasia. The abdomen of each mouse was dissected, and three fragments of the intestinal tract were collected.

[0150] result hBD2 could not be detected by HPLC in either serum or urine samples because all values ​​were below the detection level of <10 pg / ml. This indicates that hBD2 is not systemically available in mice after oral administration of 4 mg / kg (Figure 22).

[0151] Example 5 Investigation and comparison of the pharmacokinetic profiles of hBD2 fused to the C-terminus (molecular weight 71.336 Da) or N-terminus (molecular weight 71.666 Da) of human serum albumin after subcutaneous or intravenous administration of a molar equivalent dose of 1 mg / kg of hBD2 (molecular weight 66437 Da) to female NMRI mice.

[0152] material and method Treatment method: Animals were administered 10 ml / kg of stock concentration at 1.65 mg / ml according to their individual body weight (300 μL for a 30-gram mouse). A first blood sample was obtained using the submandibular gland collection method, and a second blood sample was obtained after anesthesia with soflurane and euthanasia.

[0153] result hBD2 exhibited a half-life of 1 hour, while the two fusion proteins exhibited a half-life of 12 hours. The AUC changed dramatically. Renal clearance also changed from 10 ml / min for hBD2 to 0.5–2.2 ml / min for the two fusion molecules (Figures 23, 24, 25).

[0154] This example demonstrates that the half-life of hBD2 can be significantly extended by C-terminal or N-terminal binding to albumin.

[0155] Example 6 Determination and evaluation of the anti-inflammatory effects of the "hBD2-albumin N-terminal fusion" in a mouse model of acute colitis induced by 10 days of dextran sulfate sodium (DSS) administration.

[0156] material and method Treatment method: Using a sterile 25G needle, "hBD2-albumin N-terminus" was administered intravenously or subcutaneously via the tail vein at a dosage volume of 10 ml / kg body weight. Animals received the dose once daily for 10 consecutive days. Dexamethasone (DEX), the active control, was administered subcutaneously once daily at a dosage of 1 mg / kg at a dosage volume of 10 ml / kg body weight.

[0157] result Treatment with "hBD2-albumin N-terminus" resulted in a significant suppression of the disease activity index (DAI) when administered daily via intravenous route at a dose of 1.65 mg / kg (p<0.05). Furthermore, a significant suppression of the DAI score was observed on day 10 when "hBD2-albumin N-terminus" was administered subcutaneously daily at doses of 1.65 mg / kg and 125 mg / kg, respectively (p<0.05). Administration of dextran sulfate sodium resulted in significant inflammation and damage to colonic tissue, as evident from histological examination. Treatment with "hBD2-albumin N-terminus" did not result in any statistically significant reduction of this tissue damage, nor did the active control DEX significantly reduce tissue damage. These results further showed that despite transient weight loss on days 2 and 3, animals treated with "hBD2-albumin N-terminus" exhibited a significant weight gain on day 7. In contrast, animals treated with DEX showed a very significant weight loss from day 5 onward (p<0.01).

[0158] This example demonstrates that the hBD2-albumin N-terminal fusion is biologically active in an animal model of inflammatory disease.

[0159] Example 7 Determination and evaluation of the anti-inflammatory effects of "hBD2-albumin C-terminal fusion" in a mouse model of acute colitis induced by 10 days of dextran sulfate sodium (DSS) administration.

[0160] material and method Treatment method: Using a sterile 25G needle, "hBD2-albumin C-terminus" was administered intravenously or subcutaneously via the tail vein at a dosage volume of 10 ml / kg body weight. The animals received the dose once daily for 10 consecutive days. Prednisolone (Pred), the active control, was administered orally once daily via enteral nutrition at a dosage of 1 mg / kg at a dosage volume of 10 ml / kg body weight.

[0161] result Treatment with "hBD2-albumin C-terminus" resulted in a significant suppression of DAI when administered daily via intravenous route at a dose of 1.6 mg / kg (p<0.05). Furthermore, "hBD2-albumin C-terminus" also resulted in a significant suppression of DAI when administered intravenously at a dose of 1.6 mg / kg every other day on days 0, 2, 4, 6, 8, and 10 (p<0.05) (Figure 26). Daily treatment with Pred resulted in a significant suppression of DAI on day 9 (p<0.05). Administration of dextran sulfate sodium resulted in significant inflammation and damage to colonic tissue, as evident from histological examination. Treatment with "hBD2-albumin C-terminus" at a dose of 1.6 mg / kg resulted in a statistically significant reduction in this tissue damage (p<0.05). Similarly, daily treatment with "hBD2-albumin C-terminus" at doses of 1.6 mg / kg and 16.5 mg / kg on days 0, 2, 4, 6, 8, and 10 resulted in a significant reduction in colonic tissue damage (p<0.01) (Figure 27). Treatment with Pred, the active control, did not significantly reduce tissue damage in the proximal colon, but did reduce damage in the distal colon (p<0.01). These results further showed a significant increase in body weight in animals treated with "hBD2-albumin C-terminus" (p<0.05).

[0162] This example demonstrates that the hBD2-albumin C-terminal fusion is biologically active in an animal model of inflammatory disease.

[0163] Example 8 [Table 2]

[0164] Example 9 Determination and evaluation of the efficacy of intranuclear (IN) administration versus oral administration of mammalian β-defensins in a mouse house dust mite-induced model of allergic asthma.

[0165] material and method Treatment method: Female BALB / c mice aged 7-10 weeks were randomly assigned to five test groups one day before the start of the study and sensitized subcutaneously (SC) to house dust mites (100 μg of HDM in 200 μL of saline and Freund's complete adjuvant in 0.9% saline). Mice were administered hBD2 orally and intranasally three times a day at approximately 6-hour intervals, starting on the morning of day 12, at a dose of 1.2 mg / kg / day (0.4 mg / kg TID). The final dose was administered one hour before the load on day 14. The total number of doses was 8, or the total dose of hBD2 was 2 mg / kg. Following the mice, HDM was administered intranasally (IN) on day 14 (25 μg of HDM in 50 μL of saline).

[0166] test: Airway inflammation: 48 hours after the load, bronchoalveolar lavage was performed, and the lungs were washed with three volumes of cold PBS (0.4; 0.3 and 0.3 mL (total 1 mL)). Total white blood cell count and white blood cell percentage were determined using an automated blood analyzer Sysmex XT-2000iV.

[0167] Lung function: Starting 48 hours after HDM loading, lung resistance and lung compliance were measured in anesthetized mice with cannula insertion using the Buxco Finepointe RC system from DSI after metacholine loading (MCH1, 3.125 mg / mL; MCH2, 6.25 mg / mL; MCH3, 12.5 mg / mL; and MCH4, 25 mg / mL). Data are presented as airway resistance at 10 mg / kg of metacholine and as dose-response curves.

[0168] Lung aspiration for cytokine analysis: After all BAL procedures were completed, the lungs were removed from the thoracic cavity, rapidly frozen in liquid nitrogen, and stored frozen at -80 degrees Celsius until cytokine concentration analysis of TNF-α, IL-4, IL-5, IL-6, IL-9, IL-13, and IL-33 in lung homogenates was performed by ELISA.

[0169] result Increased lung resistance and decreased lung compliance were observed in animals treated with HDM-loaded media compared to (non-asthmatic) mice loaded with saline. Inflammatory responses in mice treated with both media (oral and intranasal) were triggered by a single HDM load 14 days after HDM sensitization. The inflammatory response was characterized by a statistically significant increase (p<0.05) in total cell count, eosinophil count, neutrophil count, macrophage count, and lymphocyte count in the lung tissue homogeneous compared to saline-loaded controls. Furthermore, concentration analyses of seven cytokines—TNF-α, IL-4, IL-5, IL-6, IL-9, IL-13, and IL-33—in lung tissue homogenees revealed significantly higher levels in HDM-loaded animals compared to saline-loaded controls.

[0170] hBD2 administered on days 12–14 effectively maintained normal lung function and suppressed increased airway resistance (Figure 29) and decreased lung compliance (Figure 30) compared to animals treated with HDM-loaded media, both after oral administration three times daily and after intranasal administration (totaling 2.0 mg / kg over eight doses). An effect on cellular influx in the BALF was observed after oral administration, which significantly suppressed neutrophil count (Figure 31), although other immune cells migrated to the BALF as is typically observed in asthma. Importantly, however, the basis for cytokine storms and asthma attacks often observed in asthma was prevented by complete normalization of cytokine concentrations in lung tissue homogenates, particularly after oral administration of hBD2. Cytokine levels of TNF-α, IL-4, IL-5, IL-6, IL-9, and IL-13 after oral administration are shown in Figures 32–37. Intranasal administration of hBD2 tended to decrease TNF-α, IL-4, IL-5, IL-6, IL-9, and IL-13, but this was not statistically significant compared to the control group.

[0171] Conclusion: All results obtained demonstrate the clear protective, prophylactic, and anti-inflammatory effects of hBD2 in a house dust mite-induced mouse model of allergic asthma.

[0172] Example 10 Protection and preservation of the gastrointestinal microbiome through prophylactic treatment with defensins. Mice: Mice were housed in groups of three in four cages. Food intake was recorded daily just before lights out at 6 PM. The experimental procedures were performed on individual mice, varying the order within each group and cage. The mice were maintained at room temperature under standard SPF conditions with a 12-hour light-dark cycle. The treatment methods are described in Figure 38.

[0173] Diet: For administration, the average body weight of each mouse was estimated at 25 grams. Each mouse consumes approximately 3 grams of feed per day.

[0174] Treatment method: Mice were fed either a high-fat diet (HFD) or a low-fat (LF) control diet. The HFD consisted of four subgroups: 1. hBD2, 1. HD5, 1. hBD2 / HD5, and 1. standard HFD without defensin. The defensin concentration was 1.2 mg hBD2 per kg of mouse per day. HD5 was administered at equimolar concentrations with hBD2. The combination group received 50% hBD2 + 50% HD5, so the total amount of defensin was equivalent to that of the remaining test groups.

[0175] test: Microbial analysis was performed to investigate the gut microbiota. Longitudinal 16S characterization was carried out on a total of 240 samples, consisting of four sets of samples from 60 mice. Each mouse was sampled before dietary change, one week after dietary change, four weeks after dietary change, and at the end of the treatment, thus ensuring a complete characterization of the fecal microbiota as a result of defensin treatment.

[0176] result microbiome hBD2 primarily affected microbial abundance, while HD5 and hBD2+HD5 primarily affected microbial abundance. Figure 40 shows the relative abundance of species in different dosing groups, illustrating the significant effects of hBD2 and HD5 on the gut microbiota. A statistically significant increase in the abundance of allobaculum was observed in the small intestine after HD5 prophylaxis (p<0.02; Figure 41). Allobaculum is a species that produces short-chain fatty acids, which play an important role in regulating the homeostasis of colonic Treg cells mediated by GPCR43. A statistically significant increase in the abundance of valnesiae was observed in the colon after hBD2 prophylaxis (p<0.03; Figure 43). Valnesiae is a bacterium that can eliminate antibiotic-resistant pathogenic bacteria observed in hospitalized patients and prevent their intestinal dominance. The abundance of valnesiae corresponds to the amount of several immunomodulatory cells. Higher levels of Valnesierella in the colon were associated with higher counts of peripheral zone B cells and invariant natural killer T cells in the spleen and liver. In IL10- / - mice, higher levels of Valnesierella strains correlated with lower levels of disease activity in the development of colitis. A tendency toward decreased Lactobacillus abundance was observed in the colon after prophylactic treatment with hBD2 (p=0.1; Figure 42).

[0177] Conclusion: The lung microbiome and the microbiome appear to play a crucial role in asthma (the latter via the gut-lung axis). The significant effects of defensins on the occurrence and abundance of important commensal bacteria, as well as on colonic T cell homeostasis, can explain the difference in lung effects observed in allergic asthma mice after oral defensin treatment, as well as the difference between oral versus intranasal administration. This example 10 shows that both α and β defensins, particularly HD5 and hBD2, have a significant impact on the composition of the microbiome in terms of the number of species present and the total number of bacteria, thereby protecting and preserving a healthy microbiome. More specifically, defensins appear to promote bacteria that produce short-chain fatty acids (SCFAs), which play a crucial role in colonic Treg cell homeostasis.

[0178] Example 11 Treatment of intestinal symbiotic imbalance through defensin-based interventions.

[0179] Mice and diet This experiment aims to clarify the effects of hBD2 and HD5 on the microbiome in diet-induced obese mice. Mice were subjected to a 13-week acclimatization period on a very high-fat diet (60% of energy derived from fat) prior to the intervention. Only mice that met the criterion of a minimum weight gain of 12g (approximately 50% of initial body weight) during the acclimatization period were included in the final analysis. Mice that did not meet this criterion were housed in their respective cages as "keepers" in the hierarchy. These mice were used in all experimental tests but were excluded from the analysis.

[0180] Procedure: Before intervention, all mice were MRI scanned. Mouse cages were assigned to experimental groups based on their fat content. All subsequent measurements were paired with data from the same mice before intervention. An LFD (low-fat diet) reference group experiment was conducted in parallel. Two additional groups were included as controls for the intervention: 1. very high-fat diet and 2. low-fat diet. Experimental mice were fed the very high-fat diet during the intervention. Mice received the test diet for 10 weeks. They were co-housed in groups of 4 mice per cage and 3 cages throughout the entire experiment. All tests were conducted over 3 days, with 1 cage per group per day. The procedure is shown in Figure 39.

[0181] Tests: Test microbiological analysis was performed to investigate the gut microbiota. Longitudinal 16S characterization was carried out on a total of 240 samples, consisting of four sets of samples from 60 mice. Each mouse was sampled before diet change, one week after diet change, four weeks after diet change, and at the end of the study, thus ensuring a complete characterization of the fecal microbiota as a result of defensin treatment.

[0182] result microbiome Both defensins showed significant effects on bacterial abundance and absence. HD5 statistically significantly increased the abundance of Alloprevotella in the large intestine (p<0.02) (Figure 44), while hBD2 had no effect on the abundance of Alloprevotella. hBD2 dramatically and statistically significantly increased the relative abundance of Bifidobacteria in both the small and large intestines (p<0.0001 and p<0.04, respectively; Figure 45). HD5 tended to increase the abundance of Bifidobacteria in the small intestine (Figure 45).

[0183] The lung and gut microbiota appear to play important roles in asthma (the latter via the gut-lung axis). The significant effects of defensins on the occurrence and abundance of important commensal bacteria, as well as on colonic T cell homeostasis, can explain not only the pulmonary effects observed in allergic asthma mice after oral defensin treatment, but also the differences in pulmonary effects observed after oral versus intranasal administration.

[0184] Conclusion: This Example 11 demonstrates that both α and β-defensins, particularly hBD2 and HD5, have a significant impact on the composition of the microbiome in terms of the number of species present and the total number of bacteria, thereby protecting and maintaining a healthy microbiome. More specifically, defensins appear to promote bacteria that produce short-chain fatty acids (SCFAs), which play a crucial role in the homeostasis of colonic Treg cells.

[0185] References Bouloukaki, I. et al., 2011. Sputum and nasal lavage lung-specific biomarkers before and after smoking cessation. BMC Pulmonary Medicine 11: 35 Charlson, E.S. et al. 2011. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med 184: 957-963. Cosmi, L et al., 2011. TH17 cells: new players in asthma pathogenesis. Allergy 66: 989-998. Donia, M.S. and Fischbach, M.A. 2015. Small molecules from the human microbiota. Science 349, 1254766 Dorrestein, P.C. et al., 2014. Finding the missing links among metabolites, microbes, and the host. Immunity 40: 824-832. Ege, M.J. et al., 2011. Exposure to environmental microorganisms and childhood asthma. NEJM 364: 701-709. Essilfie, A. et al., 2015. Macrolide therapy suppresses key features of experimental steroid-sensitive and steroid-insensitive asthma. Thorax 70: 458-467. Fletcher, C. and Peto, R. 1977. The natural history of chronic airflow obstruction. BMJ: 1: 1645-1648. Hansbro, P.M. et al, 2004. Role of atypical bacterial infection on the lung in predisposition / protection of asthma. Pharmacol Ther 101: 193-210 Hansbro, P.M. et al., 2011. Cytokine / anti-cytokine therapy - novel treatments for asthma? BJP 163: 81-95. Hilty, M. et al., 2010. Disordered microbial communities in asthmatic airways. PLoS ONE5, e8578 Hogg, J.C. et al. 2004. The nature of small-airway obstruction in chronic obstructive pulmonary disease. NEJM: 350: 2645-2653. Jakobsson, H.E. et al. 2014. Decreased gut microbiota diversity, delayed Bacteroidetes colonization and reduced Th1 responses in infants delivered by Caesarian section. Gut 63: 559-566. Marra, F. et al., 2009. Antibiotic use in children is associated with increased risk of asthma. Pediatrics 123: 1003-1010. Marsland, B.J. et al., 2015. The gut-lung axis in respiratory disease. Annals ATS 12: S150-156 Penders, J. et al., 2007. The role of the intestinal microbiota in the development of atopic disorders. Allergy 2007: 1223-1236 Salzman NH, Underwood MA and Bevins CL, 2007. Paneth cells, defensins, and the commensal microbiota: a hypothesis on intimate interplay at the intestinal mucosa. Semin Immunol 19(2):70-83. Schirmer, M. et al., 2016. Linking the human gut microbiome to inflammatory cytokine production capacity. Cell 167: 1125-1136 Trompette, A. et al., 2013. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nature Medicine 20: 159-168. Wehkamp J, et al., 2002. Innate immunity and colonic inflammation: enhanced expression of epithelial alpha-defensins. Dig Dis Sci. 47(6):1349-55. Wills-Karp, M. et al., 2001. The germless theory of allergic disease: revisiting the hygiene Hypothesis. Nat Rev Immunol (1): 69-75. WO 2010 / 007166 WO 92 / 06204 WO 95 / 17413 WO 95 / 22625 US 5,223,409 WO 2013 / 007596

Claims

1. The oral or intrapulmonary administration of at least one defensin selected from the group consisting of hBD2 (SEQ ID NO:2), HD5 (SEQ ID NO:5), HD6 (SEQ ID NO:6), hBD1 (SEQ ID NO:1), hBD3 (SEQ ID NO:3), hBD4 (SEQ ID NO:4), truncated hBD2 (SEQ ID NO:7), or a functionally equivalent variant thereof differing by less than 5 amino acids, is effective to treat a disease selected from asthma, bronchiectasis, chronic obstructive pulmonary disorder (COPD), and emphysema in a subject. Treatment and / or prevention of disease Pharmaceutical compositions for use in .

2. The composition of claim 1, wherein the defensin is selected from the group consisting of hBD2 (SEQ ID NO: 2), hBD1 (SEQ ID NO: 1), hBD3 (SEQ ID NO: 3), hBD4 (SEQ ID NO: 4), and truncated hBD2 (SEQ ID NO: 7), or functionally equivalent variants thereof differing by less than 5 amino acids.

3. The composition of claim 1, wherein the defensin is hBD2 (SEQ ID NO: 2) or a functionally equivalent variant that differs from hBD2 (SEQ ID NO: 2) by fewer than 5 amino acids.

4. The disease Asthma , and Mild intermittent asthma, mild persistent asthma, moderate persistent asthma, severe persistent asthma, eosinophilic asthma, neutrophilic asthma, steroid-resistant asthma, persistent asthma Attitude and preferably steroid-resistant asthma. Please Request 1 Any one of items 〜3 Described in composition .

5. The treatment and / or prevention may involve one or more of the following: a. Restoring balance to the immune system by reducing lung tissue inflammation, inflammatory cell counts in bronchoalveolar lavage fluid, normalizing inflammatory cytokine production in lung tissue homogenates, and preventing / treating cytokine storm 、 b. Increasing lung compliance, decreasing airway hyperresponsiveness, and / or increasing peak flow in a subject in need thereof 、 c. Increasing gene richness, number of phyla, increasing butyrate production and / or tryptophan production, and decreasing acetate production of and / or from the lung microbiota 、 d. Maintaining and / or stabilizing normal pulmonary microflora , and e. To increase forced expiratory volume in 1 second (FEV1) and / or peak expiratory flow rate (PEFR), or to decrease PEFR variability 、 Includes , request request 1〜4 Either one itemDescribed in composition .

6. before The composition may include two or more defensins, such as two defensins, such as three defensins. , request request 1〜5 2. The method according to claim 1 , composition .

7. The two defensins are hBD2 and HD5. 6 Described in composition .

8. The defensin comprises at least one additional moiety selected from the group consisting of a cell penetrating peptide (CPP), an albumin binding moiety (ABM), a detectable moiety (Z), and a half-life extending peptide. , preferably an additional moiety selected from the group consisting of neonatal Fc receptor (FcRn), transferrin, albumin (HAS), XTEN or PEG, homoamino acid polymers (HAP), proline-alanine-serine polymers (PAS), or elastin-like peptides (ELP), hyaluronic acid, negatively charged highly acylated peptides such as the carboxy terminal peptide (CTP) of the chorionic gonadotropin (CG) β chain, human IgG, and molecules capable of binding to CH3(CH2)nCO- (where n is 8 to 22). Half-life extension peptides Further comprising: Claim Any one of 1 to 7 Described in composition .

9. The subject to be treated may have one or more of the following: a. >2 asthma symptoms per week, including daily symptoms and persistent symptoms 、 b. Asthma attacks of different intensities, such as attacks that affect activity and attacks that limit physical activity 、 c. >2 nocturnal asthma episodes per month, including frequent nocturnal episodes, such as >2 episodes per week lasting several days 、 d. <80% forced expiratory volume in 1 second (FEV1), such as 60-80% FEV1, <60% FEV1 , and e. Peak expiratory flow rate (PEFR) with a variation of >20%, such as a PEFR variation of 20-30%, such as a PEFR variation of >30%, such as a PEFR variation of >60% 、 Presents with , request request 1〜8 2. The method according to claim 1 , composition .

10. The defensin is selected from the group consisting of glucocorticoids, beta agonists, leukotriene receptor antagonists, theophylline, antibiotics, rifaximin, Immunosuppressants, Chemotherapy or immunotherapy , P Administered in combination with rebiotics, probiotics, tryptophan, short chain fatty acids, HNP-1, HNP-2, HNP-3, HNP-4, cathelicidin, lactoferrin, lactoferricin, lysozyme, fecal transplants, or any combination thereof , request request 1〜9 2. The method according to claim 1 , composition .

11. Daily dose is 0.5-5 mg defensin / kg, etc. Per day 0.1-10 mg defensin / kg, such as 1-2 mg defensin / kg, such as 1.2 mg defensin / kg per day , request request 1〜10 2. The method according to claim 1 , composition .

12. The defensin is administered at least once a day, such as at least twice a day, such as at least three times a day, such as at least four times a day, such as at least five times a day, or continuously. , request request 1〜11 2. The method according to claim 1 , composition .

13. The composition of any one of claims 1 to 12, wherein the administration is oral administration.

14. before Write Given, For example, by inhaler, nebulizer, or vaporizer; Endotracheal, endobronchial, or bronchoalveolar epithelium By pulmonary administration such as R , request request 1〜12 2. The method according to claim 1 , composition .